Table 2.
Effects of HIV on Statin Initiation Among Women with an Indication for Statin Use
| Indication | Statin initiators | Risk | RD (95% CI) | RR (95% CI) | HR (95% CI) | |
|---|---|---|---|---|---|---|
| 1 year risk | ||||||
| Unadjusted | ||||||
| HIV-seronegative | 150 | 12 | 0.08 | 0 | 1 | |
| HIV-seropositive | 321 | 31 | 0.10 | 0.01 (−0.04, 0.08) | 1.18 (0.66, 2.38) | |
| Weighteda | ||||||
| HIV-seronegative | 152 | 19 | 0.13 | 0 | 1 | |
| HIV-seropositive | 326 | 30 | 0.09 | −0.03 (−0.12, 0.05) | 0.73 (0.37, 1.76) | |
| 2 year risk | ||||||
| Unadjusted | ||||||
| HIV-seronegative | 150 | 23 | 0.16 | 0 | 1 | |
| HIV-seropositive | 321 | 56 | 0.18 | 0.02 (−0.07, 0.08) | 1.12 (0.68, 1.68) | |
| Weighteda | ||||||
| HIV-seronegative | 152 | 29 | 0.20 | 0 | 1 | |
| HIV-seropositive | 326 | 52 | 0.17 | −0.04 (−0.14, 0.05) | 0.82 (0.49, 1.34) | |
| 5 year risk | ||||||
| Unadjusted | ||||||
| HIV-seronegative | 150 | 40 | 0.30 | 0 | 1 | 1 |
| HIV-seropositive | 321 | 110 | 0.38 | 0.08 (−0.01, 0.17) | 1.27 (0.97, 1.74) | 1.37 (0.95, 1.97) |
| Weighteda | ||||||
| HIV-seronegative | 152 | 52 | 0.38 | 0 | 1 | 1 |
| HIV-seropositive | 326 | 104 | 0.37 | −0.01 (−0.14, 0.14) | 0.97 (0.72, 1.54) | 0.94 (0.62, 1.43) |
| 5 year risk, Stratified by Framingham Risk Scoreb | ||||||
| <10 | ||||||
| Unadjusted | ||||||
| HIV-seronegative | 112 | 27 | 0.28 | 0 | 1 | |
| HIV-seropositive | 253 | 87 | 0.38 | 0.10 (0.00, 0.20) | 1.36 (0.99, 2.02) | |
| Weighteda | ||||||
| HIV-seronegative | 106 | 31 | 0.33 | 0 | 1 | |
| HIV-seropositive | 249 | 79 | 0.36 | 0.03 (−0.10, 0.18) | 1.08 (0.78, 1.75) | |
| ≥10 | ||||||
| Unadjusted | ||||||
| HIV-seronegative | 38 | 13 | 0.37 | 0 | 1 | |
| HIV-seropositive | 68 | 23 | 0.41 | 0.04 (−0.18, 0.24) | 1.12 (0.64, 1.95) | |
| Weighteda | ||||||
| HIV-seronegative | 46 | 21 | 0.48 | 0 | 1 | |
| HIV-seropositive | 77 | 25 | 0.41 | −0.07 (−0.30, 0.22) | 0.86 (0.48, 1.91) | |
a
Weighted results are adjusted for baseline variables recorded at the first visit with an indication for a statin, and include age, race, smoking, hypertension, diabetes mellitus status, Framingham Risk Score category (<10 vs. ≥10), insurance status, total cholesterol, HDL cholesterol, LDL cholesterol, and education.
b
Results are stratified by the Framingham Risk Score (<10 vs. ≥10) at the initial statin indication.
CI, confidence interval; HR, hazard ratio; RD, risk difference; RR, risk ratio.